Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-641: pembrolizumab + enzalutamide versus placebo + enzalutamide in metastatic castration-resistant prostate cancer
MOH_2019-05-13_006052Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoints: Radiographic progression-free survival and Overall survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
pembrolizumabenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2019-05-13_006052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-13_006052.